Romiplostim in Chemotherapy-Induced Thrombocytopenia

Romiplostim in Chemotherapy-Induced Thrombocytopenia Study is for children and teens (ages 1-18) with solid tumors getting chemotherapy. Chemotherapy can cause thrombocytopenia, which means having a low number of platelets (cells that help stop bleeding). This can make it hard to continue cancer treatments. The study tests romiplostim, a medicine that might help boost platelet counts, allowing patients to keep up with their chemotherapy schedule and reduce the need for platelet transfusions. Platelet transfusions are when you get extra platelets from a donor to help your blood clot better.

• Study involves taking romiplostim to see its effects on platelet counts.
• Participants must have specific platelet count issues due to chemotherapy.
• Patients with certain conditions, like liver cancer, can't join the study.

If you or your child meet the study's conditions, it could help manage chemotherapy side effects. However, it's important to discuss with your doctor if this study is suitable for you.